drugset
drugset / Trial / NCT04036227

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248

NCT04036227 ↗

Phase 1 Completed 72 enrolled Gesynta Pharma AB CTC Clinical Trial Consultants AB · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a First in Human (FIH), double-blinded, parallel-group, randomised, placebo-controlled study designed to evaluate the safety, tolerability, PK and PD of single and multiple ascending oral doses of GS-248 in healthy subjects.

Timeline

Start
2019-07-03
Primary completion
2019-12-20
Completion
2019-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Vipoglanstat Small molecule 1 mg Oral
Subject Vipoglanstat Small molecule 5 mg Oral
Subject Vipoglanstat Small molecule 25 mg Oral
Subject Vipoglanstat Small molecule 75 mg Oral
Subject Vipoglanstat Small molecule 225 mg Oral
Subject Vipoglanstat Small molecule 450 mg Oral

Indications

No indication recorded.